{"transactions":[{"id":1396596,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-01T20:13:21.000Z","date":"2024-09-27","kind":"sale","planned":false,"acquired":false,"shares":2503,"price":20.68,"value":51762.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units."}],"balance_after":8490,"source":{"system":"sec-edgar","filing":"0001127602-24-024682","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760224024682/form4.xml","form_type":"4"}},{"id":1476999,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-17T20:24:12.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":11971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025."}],"balance_after":11971,"derivative":{"exercise_price":21.31,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":11971},"source":{"system":"sec-edgar","filing":"0001127602-24-018836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760224018836/form4.xml","form_type":"4"}},{"id":1476998,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-17T20:24:12.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":10993,"source":{"system":"sec-edgar","filing":"0001127602-24-018836","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760224018836/form4.xml","form_type":"4"}},{"id":1743629,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:43:51.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12547,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.17,"underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-117104","document":"tm2330435-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117104/tm2330435-4_4seq1.xml","form_type":"4"}},{"id":1743628,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:43:51.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12790,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16.82,"underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-23-117104","document":"tm2330435-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117104/tm2330435-4_4seq1.xml","form_type":"4"}},{"id":1743627,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:43:51.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":17.08,"underlying":"Common Stock","underlying_shares":17719},"source":{"system":"sec-edgar","filing":"0001104659-23-117104","document":"tm2330435-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117104/tm2330435-4_4seq1.xml","form_type":"4"}},{"id":1743626,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:43:51.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11625,"price":19,"value":220875.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117104","document":"tm2330435-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117104/tm2330435-4_4seq1.xml","form_type":"4"}},{"id":1743625,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T14:43:51.000Z","date":"2023-11-08","kind":"other","planned":false,"acquired":false,"shares":14766,"price":19,"value":280554.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. (\"Alfasigma\"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117104","document":"tm2330435-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117104/tm2330435-4_4seq1.xml","form_type":"4"}},{"id":1846259,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-22T21:52:41.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":10013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024."}],"balance_after":10013,"derivative":{"exercise_price":26.19,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":10013},"source":{"system":"sec-edgar","filing":"0001127602-23-019285","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760223019285/form4.xml","form_type":"4"}},{"id":1846258,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-22T21:52:41.000Z","date":"2023-06-20","kind":"grant","planned":false,"acquired":true,"shares":5007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that shall fully vest on the first anniversary of the date of grant."}],"balance_after":5007,"source":{"system":"sec-edgar","filing":"0001127602-23-019285","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760223019285/form4.xml","form_type":"4"}},{"id":1877848,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to  Purchase Common Stock","published_at":"2023-05-25T20:39:02.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":12547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":12547,"derivative":{"exercise_price":9.17,"expiration_date":"2033-05-24","underlying":"Common Stock","underlying_shares":12547},"source":{"system":"sec-edgar","filing":"0001104659-23-064841","document":"tm2317083-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064841/tm2317083-4_4seq1.xml","form_type":"4"}},{"id":1877847,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-25T20:39:02.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":8111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":26391,"source":{"system":"sec-edgar","filing":"0001104659-23-064841","document":"tm2317083-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923064841/tm2317083-4_4seq1.xml","form_type":"4"}},{"id":2220956,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-27T20:49:16.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":21412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023."}],"balance_after":21412,"derivative":{"exercise_price":26.58,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":21412},"source":{"system":"sec-edgar","filing":"0001127602-22-018169","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000112760222018169/form4.xml","form_type":"4"}},{"id":2253044,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2022-05-27T16:16:30.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":12790,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":12790,"derivative":{"exercise_price":16.82,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":12790},"source":{"system":"sec-edgar","filing":"0001104659-22-065901","document":"tm2217184-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065901/tm2217184-1_4seq1.xml","form_type":"4"}},{"id":2253043,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T16:16:30.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":7737,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders."}],"balance_after":18280,"source":{"system":"sec-edgar","filing":"0001104659-22-065901","document":"tm2217184-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922065901/tm2217184-1_4seq1.xml","form_type":"4"}},{"id":2654552,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-26T00:00:35.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":9728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022."}],"balance_after":9728,"derivative":{"exercise_price":36.01,"expiration_date":"2031-06-24","underlying":"Common Stock","underlying_shares":9728},"source":{"system":"sec-edgar","filing":"0001415889-21-003229","document":"form4-06252021_080601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000141588921003229/form4-06252021_080601.xml","form_type":"4"}},{"id":2688729,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2021-06-01T19:01:39.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":17719,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the options subject to the award shall vest and become exercisable on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021."}],"balance_after":17719,"derivative":{"exercise_price":17.08,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":17719},"source":{"system":"sec-edgar","filing":"0001104659-21-075217","document":"tm2118118-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075217/tm2118118-4_4seq1.xml","form_type":"4"}},{"id":2688728,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-01T19:01:39.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":10543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/3rd of the shares subject to the award shall vest on each anniversary of the Vesting Commencement Date (or, if earlier in any given year, the day immediately preceding the date of the Issuer's Annual Meeting of Stockholders in such year). The Vesting Commencement Date is April 1, 2021."}],"balance_after":10543,"source":{"system":"sec-edgar","filing":"0001104659-21-075217","document":"tm2118118-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921075217/tm2118118-4_4seq1.xml","form_type":"4"}},{"id":3097420,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T00:49:17.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":13953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021."}],"balance_after":13953,"derivative":{"exercise_price":33.42,"expiration_date":"2030-06-24","underlying":"Common Stock","underlying_shares":13953},"source":{"system":"sec-edgar","filing":"0001209191-20-039323","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000120919120039323/doc4.xml","form_type":"4"}},{"id":3333694,"issuer":{"id":4487,"kind":"organization","name":"Xencor Inc"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-12-20T22:16:49.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":15528,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option vest and become exercisable on December 18, 2020, and the remaining shares vest in equal monthly installments over the subsequent 24 months."}],"balance_after":15528,"derivative":{"exercise_price":38.33,"expiration_date":"2029-12-17","underlying":"Common Stock","underlying_shares":15528},"source":{"system":"sec-edgar","filing":"0001209191-19-061608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326732/000120919119061608/doc4.xml","form_type":"4"}},{"id":3501732,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Ordinary Shares","published_at":"2019-06-04T20:08:57.000Z","date":"2019-06-01","kind":"tax_withholding","acquired":false,"shares":246,"price":9.06,"value":2228.76,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,249 shares acquired under the Mallinckrodt employee stock purchase plan."}],"balance_after":23431,"source":{"system":"sec-edgar","filing":"0000950138-19-000333","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000333/edgar.xml","form_type":"4"}},{"id":3561077,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-05T20:09:39.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":34953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This amended Form 4 is being filed to correct a typographical error in the exercise price of the options which was previously reported as $22.62."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":34953,"derivative":{"exercise_price":22.26,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":34953},"source":{"system":"sec-edgar","filing":"0000950138-19-000235","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000235/edgar.xml","form_type":"4/A","original_submission_date":"2019-04-03"}},{"id":3563766,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Employee Share Options (Right to Buy)","published_at":"2019-04-03T22:13:34.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":34953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in four equal annual installments beginning April 1, 2020."}],"balance_after":34953,"derivative":{"exercise_price":22.62,"exercise_date":"2020-04-01","expiration_date":"2029-04-01","underlying":"Ordinary Shares","underlying_shares":34953},"source":{"system":"sec-edgar","filing":"0000950138-19-000231","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000231/edgar.xml","form_type":"4"}},{"id":3563765,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Ordinary Shares","published_at":"2019-04-03T22:13:34.000Z","date":"2019-04-02","kind":"tax_withholding","acquired":false,"shares":1063,"price":22.8,"value":24236.4,"ownership":{"direct":true},"balance_after":22428,"source":{"system":"sec-edgar","filing":"0000950138-19-000231","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000231/edgar.xml","form_type":"4"}},{"id":3563764,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Ordinary Shares","published_at":"2019-04-03T22:13:34.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":7638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units that vest in four equal annual installments beginning April 1, 2020."}],"balance_after":23491,"source":{"system":"sec-edgar","filing":"0000950138-19-000231","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013819000231/edgar.xml","form_type":"4"}},{"id":3904448,"issuer":{"id":28960,"kind":"organization","name":"Keenova Therapeutics plc","symbol":"NONE"},"owners":[{"id":87169,"kind":"person","name":"ROSA-BJORKESON DAGMAR","position":1,"cik":"0001643934","reported_name":"ROSA-BJORKESON DAGMAR","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strat & Corp Dev Officer"}}],"security":"Ordinary Shares","published_at":"2018-06-05T20:14:03.000Z","date":"2018-06-01","kind":"tax_withholding","acquired":false,"shares":247,"price":17.05,"value":4211.35,"ownership":{"direct":true},"balance_after":15853,"source":{"system":"sec-edgar","filing":"0000950138-18-000446","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1567892/000095013818000446/edgar.xml","form_type":"4"}}]}